Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases

Idebenone and coenzyme Q10 are novel PPARα/γ ligands, with potential for treatment of fatty liver diseases

Current peroxisome proliferator-activated receptor (PPAR)-targeted drugs, such as the PPARγ-directed diabetes drug rosiglitazone, are associated with undesirable side effects due to robust agonist activity in non-target tissues. To find new PPAR ligands with fewer toxic effects, we generated transge...

Full description

Bibliographic Details
Main Authors: Jens Tiefenbach, Lilia Magomedova, Jiabao Liu, Arkadiy A. Reunov, Ricky Tsai, Neena S. Eappen, Rebecca A. Jockusch, Corey Nislow, Carolyn L. Cummins, Henry M. Krause
Format: Article
Language:English
Published: The Company of Biologists 2018-09-01
Series:Disease Models & Mechanisms
Subjects:
Drug discovery
Fatty liver disease
Idebenone
Nuclear receptors
Zebrafish
Online Access:http://dmm.biologists.org/content/11/9/dmm034801

Internet

http://dmm.biologists.org/content/11/9/dmm034801

Similar Items